TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
ConditionColorectal Cancer; Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorTeclison Ltd.
About this trial
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Eligibility criteria
Qualifiers
Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
mCRC progressed on at least two lines of standard chemotherapy; or
NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
Measurable disease
Disqualifiers
Prior organ transplantation
Liver metastasis more than 50%
Oxygen saturation less than 92% in room air
Prior autoimmune disorder
Trial design
Treatments tested in this trial
- TATE and pembrolizumab
- TAS-102 pill
- Regorafenib Pill
Treatment groups
110 Participants
are divided into 2 treatment groupsSponsors and collaborators
Teclison Ltd.
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov